- |||||||||| decitabine / Generic mfg.
Trial completion: Phase I, Dose Escalation Study of Decitabine (clinicaltrials.gov) - Oct 15, 2018 P1, N=3, Completed, Phase classification: P1 --> P2 Active, not recruiting --> Completed
- |||||||||| Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change, Trial completion date, Combination therapy: Nilotinib Plus Pegylated Interferon-?2b in CML (clinicaltrials.gov) - Oct 12, 2018 P2, N=20, Terminated, Active, not recruiting --> Completed N=60 --> 20 | Trial completion date: Sep 2016 --> May 2016
- |||||||||| CC-90002 / Inhibrx, BMS
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Oct 9, 2018 P1, N=28, Terminated, Recruiting --> Active, not recruiting N=71 --> 28 | Trial completion date: Jul 2019 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Jul 2018; Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion
- |||||||||| CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Gene therapy: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study (clinicaltrials.gov) - Oct 2, 2018 P1/2, N=7, Completed, N=71 --> 28 | Trial completion date: Jul 2019 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Jul 2018; Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion Recruiting --> Completed | N=18 --> 7 | Trial completion date: Oct 2019 --> May 2018 | Trial primary completion date: May 2019 --> May 2018
- |||||||||| CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients (clinicaltrials.gov) - Oct 2, 2018 P1/2, N=3, Completed, Recruiting --> Completed | N=18 --> 7 | Trial completion date: Oct 2019 --> May 2018 | Trial primary completion date: May 2019 --> May 2018 Recruiting --> Completed | N=25 --> 3 | Trial completion date: Jul 2019 --> May 2018 | Trial primary completion date: Jul 2019 --> May 2018
- |||||||||| Jakafi (ruxolitinib) / Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion, Trial completion date, Trial primary completion date: Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (clinicaltrials.gov) - Oct 2, 2018 P1/2, N=5, Completed, Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2017 Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Apr 2018 | Trial primary completion date: Feb 2019 --> Mar 2018
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: EVITA-Pilot: Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study (clinicaltrials.gov) - Sep 24, 2018
P=N/A, N=20, Completed, N=144 --> 2 | Trial completion date: May 2021 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: May 2021 --> Sep 2018; "the study has been closed due to a low rate of patient enrollment (2 patients since the start of the trial)" Recruiting --> Completed | N=40 --> 20 | Trial completion date: Dec 2018 --> May 2017 | Trial primary completion date: Aug 2018 --> May 2017
- |||||||||| azacitidine / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Combination therapy: A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (clinicaltrials.gov) - Sep 14, 2018 P1, N=23, Completed, Recruiting --> Completed | N=40 --> 20 | Trial completion date: Dec 2018 --> May 2017 | Trial primary completion date: Aug 2018 --> May 2017 Active, not recruiting --> Completed | N=36 --> 23 | Trial completion date: Dec 2018 --> Aug 2018
- |||||||||| pracinostat (SB939) / Helsinn, MEI, Menarini
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome (clinicaltrials.gov) - Sep 13, 2018 P2, N=102, Completed, Active, not recruiting --> Completed | N=36 --> 23 | Trial completion date: Dec 2018 --> Aug 2018 Trial completion date: Dec 2017 --> Nov 2016 | Trial primary completion date: Dec 2017 --> Nov 2015 | Active, not recruiting --> Completed
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial suspension, Post-transplantation: Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT (clinicaltrials.gov) - Sep 5, 2018 P2, N=60, Suspended, Trial completion date: Sep 2020 --> Aug 2018 | Active, not recruiting --> Terminated; Lack of enrollment and limited funding Recruiting --> Suspended
- |||||||||| cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Aug 31, 2018 P2, N=142, Completed, N=48 --> 26 Active, not recruiting --> Completed | N=92 --> 142
- |||||||||| Tasigna (nilotinib) / Novartis, Inhibikase
Trial termination: Telemonitoring Study - for Chronic Myeloid Leukemia (CML) (clinicaltrials.gov) - Aug 13, 2018 P=N/A, N=14, Terminated, Phase classification: P=N/A --> P1 | Active, not recruiting --> Terminated; Poor accrual Completed --> Terminated; Terminated due to lack of funding
- |||||||||| volasertib (NBL-001) / Oncoheroes, Notable Labs
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Aug 9, 2018 P1, N=1, Terminated, N=48 --> 27 | Active, not recruiting --> Terminated; Study was terminated due to lack of funding N=70 --> 1 | Trial completion date: Nov 2016 --> Jul 2016 | Trial primary completion date: Nov 2016 --> Jun 2016
- |||||||||| Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion: Nilotinib in PH+, BCR-, ABL+ CML Patients (clinicaltrials.gov) - Aug 6, 2018 P3, N=109, Completed, Terminated --> Completed Active, not recruiting --> Completed
- |||||||||| Enrollment closed, Trial completion date, Trial primary completion date, Metastases: CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) - Aug 3, 2018
P=N/A, N=100000, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Oct 2019 | Trial primary completion date: Oct 2021 --> Oct 2019
- |||||||||| Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study (clinicaltrials.gov) - Jul 26, 2018
P=N/A, N=0, Withdrawn, N=300 --> 650 | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2018 --> May 2019 N=25 --> 0 | Trial completion date: Jul 2021 --> May 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2020 --> May 2018
- |||||||||| PLX51107 / Daiichi Sankyo
Phase classification, Trial completion date, Trial primary completion date, Metastases: A Study of PLX51107 in Advanced Malignancies (clinicaltrials.gov) - Jul 9, 2018 P1b/2a, N=60, Recruiting, N=11 --> 45 Phase classification: P1b --> P1b/2a | Trial completion date: Mar 2018 --> May 2019 | Trial primary completion date: Jan 2018 --> Jan 2019
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Post-transplantation: Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies (clinicaltrials.gov) - Jun 25, 2018 P1, N=2, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | N=18 --> 2 | Trial completion date: Mar 2019 --> May 2018 | Trial primary completion date: Mar 2019 --> May 2018
- |||||||||| imatinib / Generic mfg.
Enrollment change, Trial completion date, Trial termination: IDEAL: A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients (clinicaltrials.gov) - Jun 15, 2018 P4, N=55, Terminated, Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 N=150 --> 55 | Trial completion date: Aug 2019 --> Jan 2018 | Active, not recruiting --> Terminated; Sponsor's decision to halt the study.
- |||||||||| Coversin SC (nomacopan SC) / Akari Therap
Trial completion, Trial completion date: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) (clinicaltrials.gov) - Jun 4, 2018 P2, N=6, Completed, N=80 --> 12 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Mar 2018
|